Induced pluripotent stem cell (iPSC) therapies represent one of the most promising but complex frontiers in modern medicine. They offer the potential to treat conditions ranging from degenerative diseases to cancer using living, patient-administered cell therapies.
As the field edges closer to commercial viability, the manufacturing challenges involved in scaling these therapies reliably, safely and cost-effectively are becoming more pressing. Operating as one of the world's leading contract development and manufacturing (CDMO) organisations specialising in iPSC-derived cell therapies, Fujifilm Cellular Dynamics (Fujifilm) is at the forefront of that effort. Emily Letton sat down with Delara Motlagh, Chief Operating Officer, to discover more.
Scaling iPSC therapies: building for commercial reality from day one
When Fujifilm thinks about manufacturing iPSC therapies, the conversation starts long before a vial reaches a patient and well before a cell enters a bioreactor. It begins with a deceptively simple question: what exactly are you trying to make and for whom?
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.